Home › Chronic Lymphocytic Leukemia › Minnesota
Chronic Lymphocytic Leukemia clinical trials in Minnesota
29 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in Minnesota.
Cities in Minnesota
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- and 9 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT04269902A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06542250A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Mayo Clinic Rochester, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06943872A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Mayo Clinic Rochester, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277231A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Mayo Clinic Rochester, Rochester
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Mayo Clinic Rochester, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06973187A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- University of Minnesota, Minneapolis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06846671A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Regions Hospital ( Site 0042), Saint Louis Park
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06136559A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Minnesota Oncology Hematology, P.A., Coon Rapids
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218341Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Minnesota, Minneapolis
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT03666000A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Mayo Clinic Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05091424Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Mayo Clinic, Rochester
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Sanford Joe Lueken Cancer Center, Bemidji
- Essentia Health Saint Joseph's Medical Center, Brainerd
- Mercy Hospital, Coon Rapids
- and 9 more
RecruitingPhase 3
Ages 65 and older · All sexes · Updated Sep 2, 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Riverwood Healthcare Center, Aitkin
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Essentia Health - Baxter Clinic, Baxter
- and 48 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Mayo Clinic, Clinical Trials Referral Office, Rochester
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
RecruitingPhase 2
Up to age 75 · All sexes · Updated Jul 6, 2026 · NCT05805605Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
RecruitingPhase 2
Up to age 60 · All sexes · Updated Jun 25, 2026 · NCT03314974Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 24, 2026 · NCT03516617A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
- Mayo Clinic, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT07271667CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 9, 2026 · NCT04892277The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
- Mayo Clinic in Rochester, Rochester
RecruitingHealthy volunteers welcome
Ages 18 to 80 · All sexes · Updated Apr 9, 2026 · NCT05876923Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects
- Mayo Clinic in Rochester, Rochester
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Mar 31, 2026 · NCT06536452Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 25, 2026 · NCT05388006A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Mayo Clinic- Minnesota, Rochester
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Mar 2, 2026 · NCT06876649A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Mayo Clinic- Minnesota, Rochester
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Mar 2, 2026 · NCT06876662Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
- Mayo Clinic in Rochester, Rochester
RecruitingObservational study
All ages · All sexes · Updated Feb 27, 2026 · NCT06151730Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- St. Lukes Hospital of Duluth /ID# 250021, Duluth
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 9, 2026 · NCT04895436Family Study of Lymphoproliferative Disorders
- Mayo Clinic, Rochester
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 100 · All sexes · Updated Oct 14, 2025 · NCT00626496Q702 for the Treatment of Patients With Hematologic Malignancies
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 10, 2025 · NCT06712810From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.